Technology Summary. In the current economic and political climate, there has been enormous attention focused on the need to develop sustainable and renewable sources of transportation fuel. Ethanol has a significant and growing role in this development, providing a cleaner, domestically-produced, renewable energy solution. However, the current generation of ethanol production in the U.S. utilizes corn and other edible feedstocks. Mascoma is committed to developing sustainable, economically viable, next generation ethanol from cellulosic (non-food) feedstocks. In addition to using non- Mascoma Corporation, 1611380 Soldier Field Road, Boston, MA 0214202135 000-000-0000 xxx.xxxxxxx.xxx PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. food sources, processing ethanol from cellulosic biomass minimizes the environmental impact of fuel ethanol production through a more energy efficient process and lower greenhouse gas emissions. Mascoma’s industry leading R&D team is focused on developing bio-fuels from non-food biomass wood, straws, dedicated energy crops (e.g., switchgrass, miscanthus), paper pulp and other agricultural waste products. In nature, no known organism is capable of quickly and cost-effectively producing and fermenting sugars from cellulosic biomass. Mascoma’s research laboratories are now developing a new generation of microbes and processes for the economical conversion of cellulosic feedstocks into ethanol and other end products. Mascoma is developing organisms and processes designed to: • Rapidly break down the components of biomass • Convert a range of sugars and polymers of sugars to ethanol • Thrive in a manufacturing environment Mascoma Corporation has the world’s largest research team focused on the commercial development of Consolidated Bio-Processing or CBP. We are harnessing the power of nature’s best cellulose-utilizing and ethanol-fermenting microbes, simplifying the process and allowing nature to do most of the work. CBP is widely recognized as the simplest, lowest cost configuration for producing cellulosic ethanol. A simplified version of Mascoma’s process flow is illustrated in the diagram below: FRR’s initial raw material supply requirements will be 1 million wet ton’s of round wood annually for our 40 million gallons per year cellulosic ethanol plant. Our needs may be greater in...
Technology Summary. Season Electronic Controllers #RW IS Station Infra-Red Thermometer Pre- Wetting Units Anti- Icing Units AVL Hand Held Spreader Trucks Mounted Patrol Trucks Mounted # Units on Spreader Trucks # Units on Patrol Trucks 2005 30 ***12 1 13 10 15 4 0 0 *** RWIS has been used since 2004 – 2005 winter season. These sites are not County owned they are provided by the Ministry of Transportation.
Technology Summary. The development of a vaccine against human malignancies has been a long-sought goal, which has yet to be achieved. Many of the efforts toward this end have been frustrated by the lack of identification of a tumor-specific antigen which would allow tumor cells to be distinguished from normal cells. Conceptually, such an antigen could be used as a vaccine to induce the host’s immune system to reject cells bearing that antigen. NCI CRADA 01030 Immunoglobulin (Ig) molecules are composed of heavy and light chains, which possess highly specific variable regions at their amino termini. The variable regions of heavy and light chains combine to form the unique antigen-recognition site of the Ig protein. These variable regions contain determinants that can themselves be recognized as antigens, or idiotypes. B-cell malignancies are composed of clonal proliferations of cells synthesizing a single antibody molecule with unique variable regions in the heavy and light chains. B-cell lymphomas are neoplasms of mature resting and reactive lymphocytes, which generally express synthesized Ig on the cell surface. The idiotypic determinants of the surface Ig of a B-cell lymphoma can thus serve as a tumor-specific marker for the malignant clone. Studies in experimental animals, as well as in man, have demonstrated the utility of the Ig idiotype as a tumor-specific antigen (5, 6). Lxxxx and Exxxx were the first to demonstrate that active immunization against idiotypic determinants on malignant B cells could produce resistance to tumor growth, and this phenomenon of idiotype tumor resistance has been reproduced subsequently in a number of syngeneic experimental tumor models, as well as specific anti-tumor therapy against established tumors (7-16). These results, taken together, provided the rationale for testing autologous tumor-derived idiotypic surface Ig (Id) as a therapeutic “vaccine” against human B-cell lymphoma.
